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Introductory Chapter: Migraine in 




Migraine is described as a chronic, most probably genetically determined 
disease, in vast majority of patients characterized by the occurrence of headache 
attacks. The bouts of headache are accompanied by specific symptoms and signs as 
nausea—in majority of patients and vomiting—in almost half of them, as well as 
photophobia and phonophobia [1]. Since they left untreated, the attacks last—in 
adult patient—from 4 hours up to 3 days. The onset of the disease falls between 
18 and 35 years and migraine is regarded as a life-long condition, however it may 
present a different clinical face in different period of patient’s life as far as frequency 
and severity of the attacks are concerned. In general, migraine is more than twice 
more common in adult women (approx. 15% of general population) than in adult 
men—roughly 6% of the population [2], especially in the period of highest occur-
rence. However, relations and proportions might be entirely different in childhood 
and senescence—approximately the same percentage of young boys suffer from 
migraine as girls [3] and the disease is almost three times more common among 
elderly men than postmenopausal women [4].
The vast majority of the patients usually experience the moderate and/or severe 
pain intensity during attacks. It results in the fact that almost three-quarters of 
migraine victims present highly diminished effectiveness during disease attack [5]. 
It means the effective treatment of each single attack plays a decisive role in the 
reduction of both biological (i.e. pain, accompanying symptoms), social and 
economic aspects of the disease.
2. Triptans
For a long time specific and selective 5-HT1B/1D receptor agonists—a class of 
drugs called triptans (including sumatriptan, zolmitriptan, naratriptan, rizatrip-
tan, almotriptan, eletriptan, and frovatriptan)—have been used as an effective 
and relatively safe measures against migraine attacks, regarded as almost the drugs 
of choice in migraine episodes [6, 7]. The drugs were especially recommended in 
patients with attacks poorly responded to NSAIDs or in whom NSAIDs were contra-
indicated. What is more—the fewer side effects were associated with triptans than 
in other anti-migraine drugs, and triptans were more effective at aborting migraine 
bouts [8]. However, during the years of triptan administration, it was noticed, 
that these group of drugs, even used in proper dose and manner are ineffective 
in some 16–18% of migraine victims [9]. What is more the side effects of triptans 
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(coronary-like pain symptoms) appeared dangerous and strictly unacceptable for 
quite a percentage of patients [10]—in fact, triptans are contraindicated in most 
cardiovascular diseases. In these situation the strong need of new—effective and 
especially cardiac—safe migraine killers—became obvious.
3. After triptans
The next selective drugs tried in abortive treatment in migraine were ditans—a 
class of molecules that selectively bind to 5-HT1F receptors. The ditans are not 
encountered in vessels, being widespread in CNS, especially in brain stem, hamper-
ing the increased trigeminal system activity during migraine attack [11]. After the 
years of clinical studies, one of these molecules—lasmiditan, after first—relatively 
positive trials [12]—finally—has been approved by the FDA for the acute treatment 
of migraine with or without aura in adults [13].
Also the next seemingly promising group—gepants, calcitonin-gene related 
peptide (CGRP) receptor antagonist—after first enthusiastic results concerning 
the efficacy of the first generation of antagonist—telcagepant [14] or ubrogepant 
[15], were the subject of more detailed debates and considerations. The main reason 
for the doubts was their accented hepatotoxicity [16]. Eventually, the FDA has 
approved an orally disintegrating tablet formulation of rimegepant [17], that was 
the second, after ubrogepant, oral drug of this group, available in anti-migraine 
armamentarium. We still waiting for the final results and the potential approval of 
the next two molecules from second gepants generation, i.e. atogepant, vazegepant.
4.  Monoclonal antibodies against CGRP and the CGRP receptor as  
new-generation drugs for migraine treatment
Monoclonal antibodies (mAbs) developed against CGRP receptor (as erenumab) 
or CGRP molecule itself (namely—fremanezumab, galcanezumab, and eptinezumab) 
were the next big hope in therapeutic attitude to migraine. The drugs of these group 
exert strong inhibiting effect on CGRP release during migraine attack, thus hamper-
ing its vasodilative effect [18, 19]. The results of many registered pharmacoclinical 
studies/trials showed both effectiveness and safety of these drugs, that reduced both 
the number of migraine episodes, days with headache and administration of acute 
headache killers per month in migraineurs. The next advantages of these group were 
very convenient, patient-friendly dose regimen (once a four weeks) and—as it looks 
now—the absence of serious side effect [20, 21]. It seems that relatively fast onset of 
action (in the first month of implementation), high efficacy, and good tolerability 
make this class of drugs the real revolution in migraine treatment [22, 23] compared 
with that of ergotamine introduction (in 1927) or the first triptans in 1990. In fact, 
they are the second characteristic molecule—after methysergide—targeting the most 
specific mechanism of migraine attacks. This group of drugs showed effectiveness 
both in episodic and chronic migraine—and what is more, also, in migraine-like 
episodes in patients with cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL), that is quite a phenomenon [24].
We do hope that in time and gaining more experience with these group of 
antimigraine drugs, monoclonal antibodies against CGRP complex will become the 
first-line treatment of the disease.
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